Hereditary leiomyomatosis and renal cell cancer

MONDO:0007888

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a hereditary cancer syndrome characterized by a predisposition to cutaneous and uterine leiomyomas and, in some families, to renal cell cancer.

Also known as: HLRCC, Hereditary Leiomyomatosis and Renal Cell Carcinoma, MCUL, Reed syndrome, familial leiomyomatosis, familial leiomyomatosis and renal cell cancer, familial leiomyomatosis cutis et uteri, familial leiomyomatosis with renal carcinoma

40 clinical trials for this condition and its sub-types, 8 tagged with Hereditary leiomyomatosis and renal cell cancer itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Hereditary neoplastic syndrome (731)

Including sub-types (40) Tagged with Hereditary leiomyomatosis and renal cell cancer (8)

Trials to join now! 4 Not yet recruiting 1 Not yet finished but already full! 1 Terminated 2

Old drug, new hope: mercaptopurine tested against rare cancer syndrome

Disease control Not yet recruiting

This trial tests the drug mercaptopurine in people with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic condition that raises the risk of skin, uterine, and kidney tumors. The study aims to find the safest dose and see if the drug can shrink kidney canc…

Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control

Last updated Aug 08, 2026 00:03 UTC

Hereditary leiomyomatosis and renal cell cancer

Where it sits in the disease tree

Old drug, new hope: mercaptopurine tested against rare cancer syndrome